Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Cipla looks out for...

    Cipla looks out for marketing tie-up with Novartis

    Written by Ruby Khatun Khatun Published On 2017-07-18T09:53:53+05:30  |  Updated On 18 July 2017 9:53 AM IST
    Cipla looks out for marketing tie-up with Novartis

    MUMBAI: Cipla, and Novartis are looking at the possibilities to jointly market asthma drug Xolair (omalizumab) an injectable prescription medicine used to treat moderate to severe persistent asthma in patients whose symptoms are not controlled by inhaled corticosteroids.


    Lately Novartis has been exploring possibility of divesting its respiratory portfolio and many prominent Indian generic drug makers such as Lupin, Cipla, Zydus Cadila and Sun Pharmaceutical Industries are in look out to grab any such opportunity .

    Economic Times reports that Cipla had been engaged in a legal battle with Novartis since 2014 over selling of generic version of the drug Onbrez (indacaterol) being produced by Novartis, which it lost in the Delhi High Court.


    Such marketing arrangement and tie-ups between companies are very common and often formed to control each other’s distribution networks. Cipla, which is one of the oldest domestic pharmaceutical companies, is a leader in respiratory drug market in India’s netting Rs 8,500 crore.


    It has a strong and well established distribution network that would be hard to be imitated. When all the legal formalities are complete an announcement to this effect shall be made which may take about a months time, sources aware of the development informed ET.


    arrangementasthmaasthma drugCiplaCorticosteroidsDelhi high courtgenericindacaterolLupinmarketingNovartisomalizumabOnbrezSun PharmaTie UpXolairZydus Cadila
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok